Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K loaded with pharmacokinetic tables and FDA correspondence can drain hours. BioLineRx’s SEC filings are especially intricate—each Form 10-K or 10-Q nests trial endpoints for APHEXDA, royalty waterfalls, and cash-burn projections that move the share price overnight.
Stock Titan solves that problem. Our AI-powered summaries convert dense disclosures into plain English, spotlighting pipeline milestones, dilution triggers, and BioLineRx insider trading Form 4 transactions in real time. Whether you need the latest BioLineRx quarterly earnings report 10-Q filing or an alert on a sudden BioLineRx 8-K material events explained, each document arrives seconds after it hits EDGAR—already distilled into key numbers and risks.
Every filing type is covered:
- 10-K & 10-Q—drug-development timelines, liquidity runways, and revenue from commercialization, now in a BioLineRx annual report 10-K simplified format.
- Form 4—track BioLineRx executive stock transactions Form 4 to gauge management’s conviction with real-time alerts.
- DEF 14A proxy—understand BioLineRx proxy statement executive compensation without paging through appendices.
- 8-K—instant clarity on trial updates or licensing deals.
Use cases investors rely on: compare quarter-over-quarter R&D spend, monitor insider buys before catalyst dates, or verify milestone payments tied to partnerships. With AI explanations, keyword search, and side-by-side comparisons, understanding BioLineRx SEC documents with AI is finally straightforward. Dive into any BioLineRx earnings report filing analysis or browse BioLineRx Form 4 insider transactions real-time—everything you need, zero jargon.
Highbridge Capital Management disclosed a 7.2% position in BioLineRx Ltd. represented by 172,950,600 Ordinary Shares assuming exercise of warrants held by Highbridge Funds. The filing states these shares are represented by 288,251 ADSs issuable upon exercise of warrants and that each ADS represents 600 Ordinary Shares. Highbridge reports sole voting and dispositive power over the 172,950,600 Ordinary Shares. The percentage is calculated using an outstanding share base of 2,232,601,990 Ordinary Shares as reported by the issuer.
FAQ
What is the current stock price of Biolinerx (BLRX)?
What is the market cap of Biolinerx (BLRX)?
